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Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) is the major receptor of the angiogenic effects when 
linked to VEGF released by tumors. It has a well known role as a transmembrane receptor activating multiple 
signaling pathways of proliferation and migration of endothelial cells [1], thus leading to the formation and the 
expansion of new blood vessels (vasculogenesis and angiogenesis) towards the tumor [2]. Therefore, several 
approaches have been developed to inhibit VEGFR activation and signaling [3]. 
Some thienopyridine derivatives have already been shown to be inhibitors of the tyrosine kinase domain of 
VEGFR2 preventing its activation [4]. Herein, we describe the synthesis of new N-[3-(thieno[3,2-b 
]pyridine-7 -ylthio )phenyl]benzamides, suggested by rational design as potential inhibitors of this domain, either 
through a Cu-catalyzed C-N coupling of a brominated di(hetero)arylthioether thieno[3,2-b]pyridine with 
benzamides, or through a reaction of an aminated di(hetero )arylthioether thieno[3,2-b ]pyridine with benzoyl 
chlorides, as presented below. 
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The inhibition of the tyrosine kinase domain of VEGFR2 by the synthesized compounds will be evaluated by 
enzymatic and biomolecular assays using VEGF-stimulated Human Umbilical Vein Endothelial Cells 
(HUVECs). 
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